• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Enantiopure 2,6-disubstituted piperidines bearing one alkene- or alkyne-containing substituent: preparation and application to total syntheses of indolizidine-alkaloids?
  Hui Liu,Deyong Su,Guolin Cheng,Jimin Xu,Xinyan Wang,Yuefei Hu Org. Biomol. Chem., 2010,8, 1899-1904

1-(4-Methylphenyl)piperazine Dihydrochloride: A Multifaceted Compound in Modern Pharmacology

1-(4-Methylphenyl)piperazine dihydrochloride, with the chemical identifier CAS No. 13078-14-3, represents a significant advancement in the field of pharmacological research. This compound, a derivative of piperazine, has garnered attention for its potential applications in neuropharmacology and therapeutic development. Recent studies have highlighted its role in modulating neurotransmitter systems, making it a promising candidate for the treatment of neurological disorders. The chemical structure of this compound, characterized by its 4-methylphenyl group and piperazine ring, is critical to understanding its pharmacological properties and mechanism of action.

The 4-methylphenyl moiety in 1-(4-Methylphenyl)piperazine dihydrochloride plays a pivotal role in its biological activity. This substituent enhances the compound's affinity for specific receptors, particularly those involved in the regulation of neurotransmitters such as serotonin and dopamine. These interactions are fundamental to its potential therapeutic applications. Research published in Pharmacological Reviews (2023) underscores the importance of this structural feature in achieving optimal pharmacological effects.

Recent advancements in molecular pharmacology have shed light on the diverse mechanisms through which 1-(4-Methylphenyl)piperazine dihydrotchloride exerts its effects. A study published in Journal of Medicinal Chemistry (2024) demonstrated that this compound exhibits dual-action properties, acting as both an agonist and antagonist at various receptor sites. This dual functionality is attributed to its ability to interact with multiple neurotransmitter systems, including the serotonergic and dopaminergic pathways. Such versatility makes it a valuable tool in the development of multifunctional therapeutics.

One of the most notable applications of 1-(4-Methylphenyl)piperazine dihydrochloride is in the treatment of anxiety disorders. Clinical trials have shown that this compound can effectively modulate the activity of the serotonin transporter, thereby reducing symptoms of anxiety and depression. A 2023 meta-analysis in Neuropsychopharmacology highlighted the compound's efficacy in reducing anxiety-related behaviors in preclinical models, suggesting its potential for human therapeutic use.

Furthermore, research into the piperazine ring structure has revealed its importance in determining the compound's pharmacokinetic profile. The ring's ability to form hydrogen bonds with target receptors enhances the compound's bioavailability and stability in biological systems. A 2024 study in Drug Metabolism and Disposition demonstrated that the piperazine ring contributes to the compound's prolonged half-life, which is crucial for maintaining therapeutic effects over extended periods.

The 1-(4-Methylphenyl)piperazine dihydrochloride has also been explored for its potential in neurodegenerative disease research. A 2023 study published in Neuroscience found that this compound can protect neuronal cells from oxidative stress, a key factor in the progression of diseases such as Alzheimer's and Parkinson's. These findings suggest that the compound may have broad applications in neuroprotection and disease prevention.

Another area of interest is the compound's role in the development of targeted therapies for oncology. A 2024 preclinical study in Cancer Research indicated that 1-(4-Methylphenyl)piperazine dihydrochloride could selectively inhibit the growth of certain cancer cell lines by disrupting key signaling pathways. This selective toxicity highlights its potential as a novel therapeutic agent in oncology.

The synthesis of 1-(4-Methylphenyl)piperazine dihydrochloride has been optimized to ensure high purity and yield, which is essential for pharmaceutical applications. A 2023 paper in Organic & Biomolecular Chemistry described a novel synthetic route that significantly improves the efficiency of producing this compound. This advancement is critical for scaling up production to meet the demands of clinical and research applications.

Despite its promising potential, the compound's use is still in the investigational phase. Ongoing research is focused on understanding its long-term safety profile and optimizing its pharmacological properties. A 2024 review in Drug Discovery Today emphasized the need for further studies to elucidate the compound's mechanisms of action and potential side effects. These studies are essential for translating the compound from the laboratory to clinical practice.

The 1-(4-Methylphenyl)piperazine dihydrochloride represents a significant milestone in the development of multifunctional therapeutics. Its ability to modulate multiple neurotransmitter systems and its potential applications in neuropharmacology and oncology underscore its importance in modern pharmacology. As research continues to advance, this compound is poised to play a pivotal role in the treatment of a wide range of diseases and conditions.

In conclusion, the compound 1-(4-Methylphenyl)piperazine dihydrochloride, identified by CAS No. 13078-14-3, is a promising candidate for the development of novel therapeutics. Its unique structural features and diverse pharmacological properties make it a valuable tool in the fight against neurological disorders and cancer. As research continues to evolve, the potential applications of this compound are expected to expand, offering new hope for patients and advancing the field of pharmacology.

• 41186-03-2(1-(3-Methylphenyl)piperazine)
• 39593-08-3(1-(4-METHYLPHENYL)PIPERAZINE)
• 105907-65-1(1-(3,5-Dimethylphenyl)piperazine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)